NYSE:BCR - C R Bard Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
Previous Close$331.24
Today's Range$331.24 - $331.24
52-Week Range$222.42 - $337.73
VolumeN/A
Average Volume679,456 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
C. R. Bard, Inc. (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis. Its vascular products cover a range of minimally invasive devices for the treatment of peripheral vascular disease and end-stage renal disease. Its urology products include basic urology drainage products, fecal and urinary continence products, urological specialty products and Targeted Temperature Management products. Its oncology products cover a range of devices used in the treatment and management of various cancers, and other diseases and disorders. Its surgical specialty products include implanted patches and fixation devices for hernia and soft tissue repairs.

Receive BCR News and Ratings via Email

Sign-up to receive the latest news and ratings for BCR and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryHealth Care Equipment
SectorN/A
CUSIP06738310
CIK9892
Phone+1-908-2778000

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable

C R Bard (NYSE:BCR) Frequently Asked Questions

What is C R Bard's stock symbol?

C R Bard trades on the New York Stock Exchange (NYSE) under the ticker symbol "BCR."

How were C R Bard's earnings last quarter?

C R Bard Inc (NYSE:BCR) released its earnings results on Wednesday, October, 25th. The medical instruments supplier reported $3.02 EPS for the quarter, beating the consensus estimate of $2.96 by $0.06. The medical instruments supplier earned $989.80 million during the quarter, compared to the consensus estimate of $990.64 million. C R Bard's quarterly revenue was up 5.1% compared to the same quarter last year. During the same period in the prior year, the business earned $2.64 earnings per share. View C R Bard's Earnings History.

Has C R Bard been receiving favorable news coverage?

News stories about BCR stock have been trending positive recently, according to InfoTrie Sentiment. The research group scores the sentiment of news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. C R Bard earned a news sentiment score of 2.8 on InfoTrie's scale. They also assigned news articles about the medical instruments supplier a news buzz of 5.0 out of 10, indicating that recent news coverage is somewhat likely to have an impact on the company's share price in the next few days.

What other stocks do shareholders of C R Bard own?

Based on aggregate information from My MarketBeat watchlists, some companies that other C R Bard investors own include Abbott Laboratories (ABT), Becton Dickinson and (BDX), AbbVie (ABBV), Johnson & Johnson (jnj), Intuitive Surgical (ISRG), Medtronic (MDT), Baxter International (bax), Bristol-Myers Squibb (BMY), Boston Scientific (BSX) and Amgen (AMGN).

Who are C R Bard's key executives?

C R Bard's management team includes the folowing people:
  • Timothy M. Ring, Chairman of the Board, Chief Executive Officer (Age 59)
  • John H. Weiland, President, Vice Chairman of the Board, Chief Operating Officer (Age 61)
  • James C. Beasley, Group President (Age 53)
  • Timothy P. Collins, Group President (Age 56)
  • John P. Groetelaars, Group President (Age 50)
  • Christopher S. Holland, Chief Financial Officer, Senior Vice President (Age 50)
  • Samrat S. Khichi, Senior Vice President, General Counsel, Secretary (Age 49)
  • John A. DeFord Ph.D., Senior Vice President - Science, Technology and Clinical Affairs (Age 55)
  • Frank Lupisella Jr., Vice President, Controller (Age 56)
  • Betty D. Larson, Vice President - Human Resources (Age 41)

How do I buy shares of C R Bard?

Shares of BCR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is C R Bard's official website?

The official website for C R Bard is https://www.crbard.com.

How can I contact C R Bard?

C R Bard's mailing address is 730 Central Ave, NEW PROVIDENCE, NJ 07974-1139, United States. The medical instruments supplier can be reached via phone at +1-908-2778000.


MarketBeat Community Rating for C R Bard (NYSE BCR)

Community Ranking:  1.8 out of 5 (star)
Outperform Votes:  333 (Vote Outperform)
Underperform Votes:  573 (Vote Underperform)
Total Votes:  906
MarketBeat's community ratings are surveys of what our community members think about C R Bard and other stocks. Vote "Outperform" if you believe BCR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BCR will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/21/2019 by MarketBeat.com Staff

Featured Article: What is Put Option Volume?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel